Recombinant endolysins as potential therapeutics against antibiotic-resistant staphylococcus aureus: Current status of research and novel delivery strategies

Clinical Microbiology Reviews

Volumn 31, Issue 1, 2018, Pages

  Haddad Kashani, Hamed ^a   Schmelcher, Mathias ^b   Sabzalipoor, Hamed ^c   Seyed Hosseini, Elahe ^a   Moniri, Rezvan ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ETH ZURICH   (Switzerland)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Antibiotic resistance; Endolysin; Infectious diseases; Nanoparticles; Probiotic bacteria; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; BETA LACTAM; CARBAPENEM; CARBENICILLIN; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; ENDOLYSIN LYSK; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; MONOBACTAM DERIVATIVE; OXACILLIN; PENICILLIN G; PENICILLIN V; QUINOLONE; RECOMBINANT ENDOLYSIN; RECOMBINANT PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; ANTIINFECTIVE AGENT; ENDOLYSIN; PROTEINASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIOPHAGE; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME STRUCTURE; FOOD SAFETY; HEALTH CARE COST; HOST RANGE; LACTIC ACID BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE; PENICILLIN RESISTANCE; PHAGE THERAPY; PHYSICAL CHEMISTRY; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG EFFECT; RESEARCH; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; ENDOPEPTIDASES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RECOMBINANT PROTEINS; RESEARCH; STAPHYLOCOCCAL INFECTIONS;

EID: 85036522536     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00071-17     Document Type: Review

References (229)

1. Szweda P, Schielmann M, Kotlowski R, Gorczyca G, Zalewska M, Milewski S. 2012. Peptidoglycan hydrolases—potential weapons against Staphylococcus aureus. Appl Microbiol Biotechnol 96: 1157-1174. https://doi.org/10.1007/s00253-012-4484-3.
2. Schleifer KH, Kandler O. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 36:407-477.
3. Bera A, Herbert S, Jakob A, Vollmer W, Götz F. 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 55:778-787.https://doi.org/10.1111/j.1365-2958.2004.04446.x.
4. Navarre WW, Schneewind O. 1999. Surface proteins of grampositive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 63:174-229.
5. Kluytmans J, Van Belkum A, Verbrugh H. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10:505-520.
6. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339: 520-532. https://doi.org/10.1056/NEJM199808203390806.
7. Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG. 2013. Molecular epidemiology of extendedspectrum β-lactamase-, AmpC β-lactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 68:i57-i65. https://doi.org/10.1093/jac/dkt027.
8. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603-661. https://doi.org/10.1128/CMR.00134-14.
9. Kiedrowski MR, Horswill AR. 2011. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci 1241:104-121. https://doi.org/10.1111/j.1749-6632.2011.06281.x.
10. Mootz JM, Malone CL, Shaw LN, Horswill AR. 2013. Staphopains modulate Staphylococcus aureus biofilm integrity. Infect Immun 81: 3227-3238. https://doi.org/10.1128/IAI.00377-13.
11. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751-762. https://doi.org/10.1016/S1473-3099(05)70295-4.
12. Reusch M, Ghosh P, Ham C, Klotchko A, Singapuri S, Everett G. 2008. Prevalence of MRSA colonization in peripartum mothers and their newborn infants. Scand J Infect Dis 40:667-671. https://doi.org/101080/00365540801946520.
13. Stevens AM, Hennessy T, Baggett HC, Bruden D, Parks D, Klejka J. 2010. Methicillin-resistant Staphylococcus aureus carriage and risk factors for skin infections, Southwestern Alaska, USA. Emerg Infect Dis 16: 797-803. https://doi.org/10.3201/eid1605.091851.
14. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O’Boyle C. 2003. Comparison of community-and health care-associated methicillin-resistant Staphylo-coccus aureus infection. JAMA 290:2976-2984. https://doi.org/10.1001/jama.290.22.2976.
15. Pantosti A, Sanchini A, Monaco M. 2007. Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol 2:323-334. https://doi.org/10.2217/17460913.2.3.323.
16. Keeling PJ, Palmer JD. 2008. Horizontal gene transfer in eukaryotic evolution. Nat Rev Genet 9:605-618. https://doi.org/10.1038/nrg2386.
17. Gleeson A, Larkin P, Walsh C, O’Sullivan N. 2016. Methicillin-resistant Staphylococcus aureus: prevalence, incidence, risk factors, and effects on survival of patients in a specialist palliative care unit. A prospective observational study. Palliat Med 30:374-381. https://doi.org/10.1177/0269216315595158.
18. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, MacKenzie FM. 2012. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 39:273-282. https://doi.org/10.1016/j.ijantimicag.2011.09.030.
19. Tenover FC. 2006. Mechanisms of antimicrobial resistance in bacteria. Am J Med 119:S3-S10. https://doi.org/10.1016/j.amjmed.2006.03.011.
20. Hancock RE. 2005. Mechanisms of action of newer antibiotics for Clinical Microbiology Reviews Grampositive pathogens. Lancet Infect Dis 5:209-218. https://doi.org/10.1016/S1473-3099(05)70051-7.
21. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1:147-155. https://doi.org/10.1016/S1473-3099(01)00091-3.
22. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim M-N, Ploy M-C, El Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylo-coccus aureus. J Clin Microbiol 41:5-14. https://doi.org/10.1128/JCM.41.1.5-14.2003.
23. Skinner D, Keefer CS. 1941. Significance of bacteremia caused by Staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 68:851-875. https://doi.org/10.1001/archinte.1941.00200110003001.
24. Lowy FD. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111:1265-1273. https://doi.org/10.1172/JCI18535.
25. Chambers HF, DeLeo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629-641. https://doi.org/10.1038/nrmicro2200.
26. Ito T, Katayama Y, Hiramatsu K. 1999. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staph-ylococcus aureus N315. Antimicrob Agents Chemother 43:1449-1458.
27. Hartman BJ, Tomasz A. 1984. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 158:513-516.
28. Ruef C. 2004. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315-327. https://doi.org/10.1007/s15010-004-4124-7.
29. Hammes WP, Neuhaus FC. 1974. On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari. Antimicrob Agents Chemother 6:722-728. https://doi.org/10.1128/AAC.6.6.722.
30. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348:1342-1347. https://doi.org/10.1056/NEJMoa025025.
31. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569-1571. https://doi.org/10.1126/science.1090956.
32. Shoji M, Cui L, Iizuka R, Komoto A, Neoh H, Watanabe Y, Hishinuma T, Hiramatsu K. 2011. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 55:3870-3881. https://doi.org/10.1128/AAC.01563-10.
33. Hiramatsu K, Cui L, Kuroda M, Ito T. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 9:486-493. https://doi.org/10.1016/S0966-842X(01)02175-8.
34. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122-S129. https://doi.org/10.1038/nm1145.
35. Alanis AJ. 2005. Resistance to antibiotics: are we in the postantibiotic era? Arch Med Res 36:697-705. https://doi.org/10.1016/j.arcmed.2005.06.009.
36. Tang SS, Apisarnthanarak A, Hsu LY. 2014. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community-and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev 78:3-13. https://doi.org/10.1016/j.addr.2014.08.003.
37. Rayner C, Munckhof WJ. 2005. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J 35:S3-S16. https://doi.org/10.1111/j.1444-0903.2005.00976.x.
38. Cosgrove SE, Vigliani GA, Campion M, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW. 2009. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713-721. https://doi.org/10.1086/597031.
39. Gardete S, Tomasz A. 2014. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 124:2836-2840. https://doi.org/10.1172/JCI68834.
40. Loomba PS, Taneja J, Mishra B. 2010. Methicillin and vancomycin resistant S. aureus in hospitalized patients. J Glob Infect Dis 2:275-283. https://doi.org/10.4103/0974-777X.68535.
41. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481-1490. https://doi.org/10.1086/340353.
42. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2012. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4-11. https://doi.org/10.1093/jac/dks354.
43. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47:2538-2544.https://doi.org/10.1128/AAC.47.8.2538-2544.2003.
44. Straus SK, Hancock RE. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 1758: 1215-1223. https://doi.org/10.1016/j.bbamem.2006.02.009.
45. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139-158. https://doi.org/10.1111/j.1749-6632.2012.06819.x.
46. Siala W, Mingeot-Leclercq M-P, Tulkens PM, Hallin M, Denis O, Van Bambeke F. 2014. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone dela-floxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 58:6385-6397. https://doi.org/10.1128/AAC.03482-14.
47. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. 2009. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 53:3552-3560. https://doi.org/10.1128/AAC.00418-09.
48. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. 2014. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22:438-445. https://doi.org/10.1016/j.tim.2014.04.007.
49. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. 2007. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61:26-38. https://doi.org/10.1093/jac/dkm416.
50. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. https://doi.org/10.1086/595011.
51. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, Lesher LJ, Lynfield R. 2010. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 31:365-373. https://doi.org/10.1086/651094.
52. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 2013. Antibiotic resistance—the need for global solutions. Lancet Infect Dis 13:1057-1098. https://doi.org/10.1016/S1473-3099(13)70318-9.
53. Fernandes P. 2006. Antibacterial discovery and development—the failure of success? Nat Biotechnol 24:1497-1503. https://doi.org/10.1038/nbt1206-1497.
54. Papich MG. 2012. Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs? Vet Dermatol 23:352-364. https://doi.org/10.1111/j.1365-3164.2011.01030.x.
55. Seed KD, Lazinski DW, Calderwood SB, Camilli A. 2013. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature 494:489-491. https://doi.org/10.1038/nature11927.
56. Pires DP, Boas DV, Sillankorva S, Azeredo J. 2015. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89:7449-7456. https://doi.org/10.1128/JVI.00385-15.
57. Twort FW. 1915. An investigation on the nature of ultra-microscopic viruses. Lancet 186:1241-1243. https://doi.org/10.1016/S0140-6736(01)20383-3.
58. Salmond GP, Fineran PC. 2015. A century of the phage: past, present and future. Nat Rev Microbiol 13:777-786. https://doi.org/10.1038/nrmicro3564.
59. Summers WC. 2001. Bacteriophage therapy. Annu Rev Microbiol 55: 437-451. https://doi.org/10.1146/annurev.micro.55.1.437.
60. Hanlon GW. 2007. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30:118-128. https://doi.org/10.1016/j.ijantimicag.2007.04.006.
61. Lavigne R, Robben J. 2012. Professor Dr. Richard Bruynoghe: a 1951 overview of his bacteriophage research spanning three decades, vol 2, p 1-4. Taylor & Francis, London, United Kingdom.
62. Atterbury R. 2009. Bacteriophage biocontrol in animals and meat products. Microb Biotechnol 2:601-612. https://doi.org/10.1111/j.1751-7915.2009.00089.x.
63. Nelson EJ, Harris JB, Morris JG, Jr, Calderwood SB, Camilli A. 2009. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Microbiol 7:693-702. https://doi.org/10.1038/nrmicro2204.
64. Endersen L, O’Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. 2014. Phage therapy in the food industry. Annu Rev Food Sci Technol 5:327-349. https://doi.org/10.1146/annurev-food-030713-092415.
65. Schmelcher M, Donovan DM, Loessner MJ. 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147-1171. https://doi.org/10.2217/fmb.12.97.
66. Garcia P, Rodriguez L, Rodriguez A, Martinez B. 2010. Food biopreservation: promising strategies using bacteriocins, bacterio-phages and endolysins. Trends Food Sci Technol 21:373-382. https://doi.org/10.1016/j.tifs.2010.04.010.
67. Clark JR, March JB. 2006. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 24:212-218. https://doi.org/10.1016/j.tibtech.2006.03.003.
68. Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy. Curr Opin Microbiol 14:524-531. https://doi.org/10.1016/j.mib.2011.07.028.
69. Rodríguez-Rubio L, Martínez B, Donovan DM, Rodríguez A, García P. 2013. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol 39:427-434. https://doi.org/10.3109/1040841X.2012.723675.
70. Young R. 2013. Phage lysis: do we have the hole story yet? Curr Opin Microbiol 16:790-797. https://doi.org/10.1016/j.mib.2013.08.008.
71. Fischetti VA. 2010. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 300:357-362. https://doi.org/10.1016/j.ijmm.2010.04.002.
72. Loessner MJ. 2005. Bacteriophage endolysins— current state of research and applications. Curr Opin Microbiol 8:480-487. https://doi.org/10.1016/j.mib.2005.06.002.
73. Briers Y, Schmelcher M, Loessner MJ, Hendrix J, Engelborghs Y, Volckaert G, Lavigne R. 2009. The high-affinity peptidoglycan binding do main of Pseudomonas phage endolysin KZ144. Biochem Biophys Res Commun 383:187-191. https://doi.org/10.1016/j.bbrc.2009.03.161.
74. Becker SC, Foster-Frey J, Stodola AJ, Anacker D, Donovan DM. 2009. Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443:32-41. https://doi.org/10.1016/j.gene.2009.04.023.
75. Donovan DM, Foster-Frey J, Dong S, Rousseau GM, Moineau S, Pritchard DG. 2006. The cell lysis activity of the Streptococcus agalactiae bacteriophage B30 endolysin relies on the cysteine, histidine-dependent amidohydrolase/peptidase domain. Appl Environ Microbiol 72:5108-5112. https://doi.org/10.1128/AEM.03065-05.
76. Fernandes S, Proença D, Cantante C, Silva FA, Leandro C, Lourenço S, Milheiriço C, de Lencastre H, Cavaco-Silva P, Pimentel M. 2012. Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb Drug Resist 18: 333-343. https://doi.org/10.1089/mdr.2012.0025.
77. Sass P, Bierbaum G. 2007. Lytic activity of recombinant bacteriophage 11 and 12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 73:347-352. https://doi.org/10.1128/AEM.01616-06.
78. Schmelcher M, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, Loessner MJ, Dong S, Pritchard DG, Lee JC. 2015. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J Antimicrob Chemother 70:1453-1465. https://doi.org/10.1093/jac/dku552.
79. Pritchard DG, Dong S, Baker JR, Engler JA. 2004. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 150:2079-2087. https://doi.org/10.1099/mic.0.27063-0.
80. Loessner MJ, Kramer K, Ebel F, Scherer S. 2002. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 44:335-349. https://doi.org/10.1046/j.1365-2958.2002.02889.x.
81. Zimmer M, Vukov N, Scherer S, Loessner MJ. 2002. The murein hydrolase of the bacteriophage 3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl Environ Microbiol 68: 5311-5317. https://doi.org/10.1128/AEM.68.11.5311-5317.2002.
82. Low LY, Yang C, Perego M, Osterman A, Liddington R. 2011. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins. J Biol Chem 286:34391-34403. https://doi.org/10.1074/jbc.M111.244160.
83. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC: a multimeric bacteriophage lysin. Proc Natl Acad Sci U S A 103: 10765-10770. https://doi.org/10.1073/pnas.0604521103.
84. Cheng X, Zhang X, Pflugrath JW, Studier FW. 1994. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. Proc Natl Acad Sc i U S A 91:4034-4038.https://doi.org/10.1073/pnas.91.9.4034.
85. Sagermann M, Matthews BW. 2002. Crystal structures of a T4-lysozyme duplication-extension mutant demonstrate that the highly conserved β-sheet region has low intrinsic folding propensity. J Mol Biol 316: 931-940. https://doi.org/10.1006/jmbi.2001.5376.
86. Resch G, Moreillon P, Fischetti VA. 2011. A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int J Antimicrob Agents 38:516-521. https://doi.org/10.1016/j.ijantimicag.2011.08.009.
87. McGowan S, Buckle AM, Mitchell MS, Hoopes JT, Gallagher DT, Heselpoth RD, Shen Y, Reboul CF, Law RH, Fischetti VA. 2012. X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc Natl Acad Sci U S A 109:12752-12757. https://doi.org/10.1073/pnas.1208424109.
88. Low LY, Yang C, Perego M, Osterman A, Liddington RC. 2005. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem 280:35433-35439. https://doi.org/10.1074/jbc.M502723200.
89. Porter CJ, Schuch R, Pelzek AJ, Buckle AM, McGowan S, Wilce MC, Rossjohn J, Russell R, Nelson D, Fischetti VA. 2007. The 1.6 Å crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J Mol Biol 366:540-550. https://doi.org/10.1016/j.jmb.2006.11.056.
90. Korndörfer IP, Danzer J, Schmelcher M, Zimmer M, Skerra A, Loessner MJ. 2006. The crystal structure of the bacteriophage PSA endolysin reveals a unique fold responsible for specific recognition of Listeria cell walls. J Mol Biol 364:678-689. https://doi.org/10.1016/j.jmb.2006.08.069.
91. Gu J, Feng Y, Feng X, Sun C, Lei L, Ding W, Niu F, Jiao L, Yang M, Li Y. 2014. Structural and biochemical characterization reveals LysGH15 as an unprecedented “EF-hand-like“ calcium-binding phage lysin. PLoS Pathog 10:e1004109. https://doi.org/10.1371/journal.ppat.1004109.
92. Hermoso JA, Monterroso B, Albert A, Galán B, Ahrazem O, García P, Martínez-Ripoll M, García JL, Menéndez M. 2003. Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11:1239-1249. https://doi.org/10.1016/j.str.2003.09.005.
93. Schmelcher M, Loessner MJ. 2016. Bacteriophage endolysins: applications for food safety. Curr Opin Biotechnol 37:76-87. https://doi.org/10.1016/j.copbio.2015.10.005.
94. Ajuebor J, McAuliffe O, O’Mahony J, Ross RP, Hill C, Coffey A. 2016. Bacteriophage endolysins and their applications. Sci Prog 99:183-199.
95. Fischetti VA. 2005. Bacteriophage lytic enzymes: novel antiinfectives. Trends Microbiol 13:491-496. https://doi.org/10.1016/j.tim.2005.08.007.
96. Borysowski J, Weber-Dąbrowska B, Górski A. 2006. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (May-wood) 231:366-377. https://doi.org/10.1177/153537020623100402.
97. Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF. 2007. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother 51:475-482. https://doi.org/10.1128/AAC.00786-06.
98. Viertel TM, Ritter K, Horz H-P. 2014. Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother 69:2326-2336. https://doi.org/10.1093/jac/dku173.
99. Spratt BG. 1994. Resistance to antibiotics mediated by target alterations. Science 264(5157):388-393. https://doi.org/10.1126/science.8153626.
100. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett 294:52-60. https://doi.org/10.1111/j.1574-6968.2009.01541.x.
101. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM. 2012. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol 78:2297-2305. https://doi.org/10.1128/AEM.07050-11.
102. Becker SC, Foster-Frey J, Donovan DM. 2008. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett 287:185-191. https://doi.org/10.1111/j.1574-6968.2008.01308.x.
103. Haddad Kashani H, Fahimi H, Goli YD, Moniri R. 2017. A novel chimeric endolysin with antibacterial activity against methicillin-resistant Staphylococcus aureus. Front Cell Infect Microbiol 7:290. https://doi.org/10.3389/fcimb.2017.00290.
104. Mao J, Schmelcher M, Harty WJ, Foster-Frey J, Donovan DM. 2013. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol Lett 342:30-36. https://doi.org/10.1111/1574-6968.12104.
105. Yang H, Yu J, Wei H. 2014. Engineered bacteriophage lysins as novel anti-infectives. Front Microbiol 5:542. https://doi.org/10.3389/fmicb.2014.00542.
106. Donovan DM, Foster-Frey J. 2008. LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5 domain for antimicrobial lysis of streptococci. FEMS Microbiol Lett 287:22-33. https://doi.org/10.1111/j.1574-6968.2008.01287.x.
107. Schindler CA, Schuhardt V. 1964. Lysostaphin: a new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci U S A 51:414-421. https://doi.org/10.1073/pnas.51.3.414.
108. Gründling A, Missiakas DM, Schneewind O. 2006. Staphylococcus aureus mutants with increased lysostaphin resistance. J Bacteriol 188: 6286-6297. https://doi.org/10.1128/JB.00457-06.
109. Verbree CT, Dätwyler SM, Meile S, Eichenseher F, Donovan DM, Loessner MJ, Schmelcher M. 2017. Identification of peptidoglycan hydrolase constructs with synergistic staphylolytic activity in cow’s milk. Appl Environ Microbiol 83:e03445-16.https://doi.org/10.1128/AEM.03445-16.
110. Schmelcher M, Tchang VS, Loessner MJ. 2011. Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb Biotechnol 4:651-662. https://doi.org/10.1111/j.1751-7915.2011.00263.x.
111. Gaeng S, Scherer S, Neve H, Loessner MJ. 2000. Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Appl Environ Microbiol 66:2951-2958. https://doi.org/10.1128/AEM.66.7.2951-2958.2000.
112. Mayer MJ, Garefalaki V, Spoerl R, Narbad A, Meijers R. 2011. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol 193:5477-5486. https://doi.org/10.1128/JB.00439-11.
113. Pritchard DG, Dong S, Kirk MC, Cartee RT, Baker JR. 2007. LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae. Appl Environ Microbiol 73:7150-7154. https://doi.org/10.1128/AEM.01783-07.
114. Becker SC, Roach DR, Chauhan VS, Shen Y, Foster-Frey J, Powell AM, Bauchan G, Lease RA, Mohammadi H, Harty WJ. 2016. Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 6:25063. https://doi.org/10.1038/srep25063.
115. Manoharadas S, Witte A, Bläsi U. 2009. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J Biotechnol 139: 118-123. https://doi.org/10.1016/j.jbiotec.2008.09.003.
116. Roach DR, Donovan DM. 2015. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5:e1062590. https://doi.org/10.1080/21597081.2015.1062590.
117. Navarre WW, Ton-That H, Faull KF, Schneewind O. 1999. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage 11: identification of a D-alanyl-glycine endopeptidase activity. J Biol Chem 274:15847-15856. https://doi.org/10.1074/jbc.274.22.15847.
118. Gründling A, Schneewind O. 2006. Crosslinked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J Bacteriol 188:2463-2472. https://doi.org/10.1128/JB.188.7.2463-2472.2006.
119. Abaev I, Foster-Frey J, Korobova O, Shishkova N, Kiseleva N, Kopylov P, Pryamchuk S, Schmelcher M, Becker SC, Donovan DM. 2013. Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an interlyticdomain secondary translational start site. Appl Microbiol Biotechnol 97:3449-3456. https://doi.org/10.1007/s00253-012-4252-4.
120. Linden SB, Zhang H, Heselpoth RD, Shen Y, Schmelcher M, Eichenseher F, Nelson DC. 2015. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol 99:741-752. https://doi.org/10.1007/s00253-014-5930-1.
121. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603-1612. https://doi.org/10.1128/AAC.01625-09.
122. Sanz-Gaitero M, Keary R, Garcia-Doval C, Coffey A, van Raaij MJ. 2014. Crystal structure of the lytic CHAP K domain of the endolysin LysK from Staphylococcus aureus bacteriophage K. Virol J 11:133. https://doi.org/10.1186/1743-422X-11-133.
123. Becker SC, Swift S, Korobova O, Schischkova N, Kopylov P, Donovan DM, Abaev I. 2015. Lytic activity of the staphylolytic Twort phage endolysin CHAP domain is enhanced by the SH3b cell wall binding domain. FEMS Microbiol Lett 362:1-8. https://doi.org/10.1093/femsle/fnu019.
124. O’Flaherty S, Coffey A, Meaney W, Fitzgerald G, Ross R. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187:7161-7164. https://doi.org/10.1128/JB.187.20.7161-7164.2005.
125. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K-I, Muraoka A, Sugai M, Hiramatsu K. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage MR11. J Infect Dis 196:1237-1247. https://doi.org/10.1086/521305.
126. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and-sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 55:738-744. https://doi.org/10.1128/AAC.00890-10.
127. Schmelcher M, Powell AM, Camp MJ, Pohl CS, Donovan DM. 2015. Synergistic streptococcal phage SA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl Microbiol Biotechnol 99:8475-8486. https://doi.org/10.1007/s00253-015-6579-0.
128. Singh PK, Donovan DM, Kumar A. 2014. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother 58:4621-4629. https://doi.org/10.1128/AAC.00126-14.
129. Fischetti V, Loomis L. April 2005. Method for the treatment of bacterial eye infections. US patent 10/135,824.
130. O’Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald G, Ross R. 2004. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G C content. J Bacteriol 186:2862-2871. https://doi.org/10.1128/JB.186.9.2862-2871.2004.
131. Horgan M, O’Flynn G, Garry J, Cooney J, Coffey A, Fitzgerald GF, Ross RP, McAuliffe O. 2009. Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staph-ylococci. Appl Environ Microbiol 75:872-874. https://doi.org/10.1128/AEM.01831-08.
132. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K. 2011. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother 55: 4416-4419. https://doi.org/10.1128/AAC.00217-11.
133. Idelevich EA, Schaumburg F, Knaack D, Scherzinger AS, Mutter W, Peters G, Peschel A, Becker K. 2016. The recombinant bacteriophage endolysin HY-133 exhibits in vitro activity against different African clonal lineages of the Staphylococcus aureus complex, including Staph-ylococcus schweitzeri. Antimicrob Agents Chemother 60:2551-2553. https://doi.org/10.1128/AAC.02859-15.
134. Filatova LY, Becker SC, Donovan DM, Gladilin AK, Klyachko NL. 2010. LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization. Biochimie 92:507-513. https://doi.org/10.1016/j.biochi.2010.01.026.
135. Filatova LY, Donovan DM, Foster-Frey J, Pugachev VG, Dmitrieva NF, Chubar TA, Klyachko NL, Kabanov AV. 2015. Bacteriophage phi11 lysin: physicochemical characterization and comparison with phage phi80 lysin. Enzyme Microb Technol 73:51-58. https://doi.org/10.1016/j.enzmictec.2015.03.005.
136. Sanz-Gaitero M, Keary R, Garcia-Doval C, Coffey A, van Raaij MJ. 2013. Crystallization of the CHAP domain of the endolysin from Staphylococcus aureus bacteriophage K. Acta Crystallogr Sect F Struct Biol Cryst Commun 69:1393-1396. https://doi.org/10.1107/S1744309113030133.
137. Jun SY, Jung GM, Yoon SJ, Oh M-D, Choi Y-J, Lee WJ, Kong J-C, Seol JG, Kang SH. 2013. Antibacterial properties of a preformulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents 41:156-161. https://doi.org/10.1016/j.ijantimicag.2012.10.011.
138. Jun SY, Jung GM, Yoon SJ, Youm SY, Han HY, Lee JH, Kang SH. 2016. Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period. Clin Exp Pharmacol Physiol 43:1013-1016. https://doi.org/10.1111/1440-1681.12613.
139. Jun SY, Jung GM, Son J-S, Yoon SJ, Choi Y-J, Kang SH. 2011. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother 55:1764-1767. https://doi.org/10.1128/AAC.01097-10.
140. Jun SY, Jang IJ, Yoon S, Jang K, Yu K-S, Cho JY, Seong M-W, Jung GM, Yoon SJ, Kang SH. 2017. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother 61:e02629-16. https://doi.org/10.1128/AAC.02629-16.
141. O’Flaherty S, Ross R, Meaney W, Fitzgerald G, Elbreki M, Coffey A. 2005. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 71:1836-1842. https://doi.org/10.1128/AEM.71.4.1836-1842.2005.
142. Fenton M, Ross R, McAuliffe O, O’Mahony J, Coffey A. 2011. Characterization of the staphylococcal bacteriophage lysin CHAPK. J Appl Microbiol 111:1025-1035. https://doi.org/10.1111/j.1365-2672.2011.05119.x.
143. Fenton M, Keary R, McAuliffe O, Ross RP, O’Mahony J, Coffey A. 2013. Bacteriophage-derived peptidase eliminates and prevents staphylococcal biofilms. Int J Microbiol 2013:625341. https://doi.org/10.1155/2013/625341.
144. Fenton M, Casey PG, Hill C, Gahan CG, McAuliffe O, O’Mahony J, Maher F, Coffey A. 2010. The truncated phage lysin CHAPk eliminates Staphylococcus aureus in the nares of mice. Bioeng Bugs 1:404-407. https://doi.org/10.4161/bbug.1.6.13422.
145. Gu J, Lu R, Liu X, Han W, Lei L, Gao Y, Zhao H, Li Y, Diao Y. 2011. LysGH15B, the SH3b domain of staphylococcal phage endolysin LysGH15, retains high affinity to staphylococci. Curr Microbiol 63: 538-542. https://doi.org/10.1007/s00284-011-0018-y.
146. Jun SY, Jung GM, Yoon SJ, Choi Y-J, Koh WS, Moon KS, Kang SH. 2014. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 58:2084-2088. https://doi.org/10.1128/AAC.02232-13.
147. Hennekinne J-A, De Buyser M-L, Dragacci S. 2012. Staphylococcus aureus and its food poisoning toxins: characterization and outbreak investigation. FEMS Microbiol Rev 36:815-836. https://doi.org/10.1111/j.1574-6976.2011.00311.x.
148. Iwamoto M, Ayers T, Mahon BE, Swerdlow DL. 2010. Epidemiology of seafood-associated infections in the United States. Clin Microbiol Rev 23:399-411. https://doi.org/10.1128/CMR.00059-09.
149. Reddy G, Altaf M, Naveena B, Venkateshwar M, Kumar EV. 2008. Amylolytic bacterial lactic acid fermentation—a review. Biotechnol Adv 26:22-34. https://doi.org/10.1016/j.biotechadv.2007.07.004.
150. Wegmann U, O’Connell-Motherway M, Zomer A, Buist G, Shearman C, Canchaya C, Ventura M, Goesmann A, Gasson MJ, Kuipers OP. 2007. Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363. J Bacteriol 189:3256-3270. https://doi.org/10.1128/JB.01768-06.
151. Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermúdez-Humarán LG, Nouaille S, Ribeiro LA, Leclercq S, Gabriel JE. 2005. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 4:2. https://doi.org/10.1186/1475-2859-4-2.
152. Mierau I, Kleerebezem M. 2005. 10 years of the nisin-controlled gene cmr.asm.org 23 Haddad Kashani et al. expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68:705-717. https://doi.org/10.1007/s00253-005-0107-6.
153. Jørgensen CM, Vrang A, Madsen SM. 2014. Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett 351:170-178. https://doi.org/10.1111/1574-6968.12351.
154. Morello E, Bermudez-Humaran L, Llull D, Sole V, Miraglio N, Langella P, Poquet I. 2008. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. J Mol Microbiol Biotechnol 14:48-58. https://doi.org/10.1159/000106082.
155. Turner MS, Waldherr F, Loessner MJ, Giffard PM. 2007. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Syst Appl Microbiol 30:58-67. https://doi.org/10.1016/j.syapm.2006.01.013.
156. De Ruyter P, Kuipers OP, De Vos WM. 1996. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62:3662-3667.
157. Rodríguez-Rubio L, Gutiérrez D, Martínez B, Rodríguez A, García P. 2012. Lytic activity of LysH5 endolysin secreted by Lactococcus lactis using the secretion signal sequence of bacteriocin Lcn972. Appl Environ Microbiol 78:3469-3472. https://doi.org/10.1128/AEM.00018-12.
158. Huang WC, Tsai PJ, Chen YC. 2009. Multifunctional Fe3O4@Au nanoeggs as photothermal agents for selective killing of nosocomial and antibiotic-resistant bacteria. Small 5:51-56. https://doi.org/10.1002/smll.200801042.
159. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD. 2004. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-767. https://doi.org/10.1002/ijc.20048.
160. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI. 2008. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-896. https://doi.org/10.1021/nn800072t.
161. Choi K-H, Lee H-J, Park BJ, Wang K-K, Shin EP, Park J-C, Kim YK, Oh M-K, Kim Y-R. 2012. Photosensitizer and vancomycin-conjugated novel multifunctional magnetic particles as photoinactivation agents for selective killing of pathogenic bacteria. Chem Commun (Camb) 48: 4591-4593. https://doi.org/10.1039/c2cc17766h.
162. Kell AJ, Stewart G, Ryan S, Peytavi R, Boissinot M, Huletsky A, Bergeron MG, Simard B. 2008. Vancomycin-modified nanoparticles for efficient targeting and preconcentration of Gram-positive and Gram-negative bacteria. ACS Nano 2:1777-1788. https://doi.org/10.1021/nn700183g.
163. Li J, Wang L, Benicewicz BC. 2013. Synthesis of Janus nanoparticles via a combination of the reversible click reaction and “grafting to” strategies. Langmuir 29:11547-11553. https://doi.org/10.1021/la401990d.
164. Li Y, Krentz TM, Wang L, Benicewicz BC, Schadler LS. 2014. Ligand engineering of polymer nanocomposites: from the simple to the complex. ACS Appl Mater Interfaces 6:6005-6021. https://doi.org/10.1021/am405332a.
165. Wang X, Zhu S, Liu L, Li L. 2017. Flexible antibacterial film based on conjugated polyelectrolyte/silver nanocomposites. ACS Appl Mater Interfaces 9:9051-9058. https://doi.org/10.1021/acsami.7b00885.
166. Wang L, Chen YP, Miller KP, Cash BM, Jones S, Glenn S, Benicewicz BC, Decho AW. 2014. Functionalised nanoparticles complexed with antibiotic efficiently kill MRSA and other bacteria. Chem Commun (Camb) 50:12030-12033. https://doi.org/10.1039/C4CC04936E.
167. Miller KP, Wang L, Chen Y-P, Pellechia PJ, Benicewicz BC, Decho AW. 2015. Engineering nanoparticles to silence bacterial communication. Front Microbiol 6:189. https://doi.org/10.3389/fmicb.2015.00189.
168. Cho EC, Au L, Zhang Q, Xia Y. 2010. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small 6:517-522. https://doi.org/10.1002/smll.200901622.
169. Rosemary M, MacLaren I, Pradeep T. 2006. Investigations of the antibacterial properties of ciprofloxacin@SiO2. Langmuir 22:10125-10129. https://doi.org/10.1021/la061411h.
170. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. 2006. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312:1027-1030. https://doi.org/10.1126/science.1125559.
171. Thomas M, Klibanov AM. 2003. Conjugation to gold nanoparticles enhances polyethylenimine’s transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sc i U S A 100:9138-9143.https://doi.org/10.1073/pnas.1233634100.
172. Bowman M-C, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. 2008. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 130:6896-6897. https://doi.org/10.1021/ja710321g.
173. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, Xie J, Kim C, Schwartz AG, Wang LV. 2009. Gold nanocages covered by smart polymers for controlled release with nearinfrared light. Nat Mater 8:935-939. https://doi.org/10.1038/nmat2564.
174. Hyland RM, Beck P, Mulvey GL, Kitov PI, Armstrong GD. 2006. N-Acetyllactosamine conjugated to gold nanoparticles inhibits enteropathogenic Escherichia coli colonization of the epithelium in human intestinal biopsy specimens. Infect Immun 74:5419-5421. https://doi.org/10.1128/IAI.00739-06.
175. Hyland RM, Griener TP, Mulvey GL, Kitov PI, Srivastava OP, Marcato P, Armstrong GD. 2006. Basis for N-acetyllactosamine-mediated inhibition of enteropathogenic Escherichia coli localized adherence. J Med Microbiol 55:669-675. https://doi.org/10.1099/jmm.0.46344-0.
176. Rao J. 2008. Shedding light on tumors using nanoparticles. ACS Nano 2:1984-1986. https://doi.org/10.1021/nn800669n.
177. Natan M, Banin E. 2017. From nano to micro: using nanotechnology to combat microorganisms and their multidrug resistance. FEMS Microbiol Rev 41:302-322. https://doi.org/10.1093/femsre/fux003.
178. Xu P, Liang J, Cao X, Tang J, Gao J, Wang L, Shao W, Gao Q, Teng Z. 2016. Facile synthesis of monodisperse of hollow mesoporous SiO2 nanoparticles and insitu growth of Ag nanoparticles for antibacterial. J Colloid Interface Sci 474:114-118. https://doi.org/10.1016/j.jcis.2016.04.009.
179. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT, Venketesan R. 2010. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine (Lond) 6:103-109. https://doi.org/10.1016/j.nano.2009.04.006.
180. Manikprabhu D, Lingappa K. 2013. Antibacterial activity of silver nano-particles against methicillin-resistant Staphylococcus aureus synthesized using model Streptomyces sp. pigment by photoirradiation method. J Pharm Res 6:255-260.
181. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. 2007. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine (Lond) 3:168-171. https://doi.org/10.1016/j.nano.2007.02.001.
182. Teng T, Liu J, Wei H. 2015. Antimycobacterial peptides: from human to phage. Cell Physiol Biochem 35:452-466. https://doi.org/10.1159/000369711.
183. Schmelcher M, Waldherr F, Loessner MJ. 2012. Listeria bacterio-phage peptidoglycan hydrolases feature high thermoresistance and reveal increased activity after divalent metal cation substitution. Appl Microbiol Biotechnol 93:633-643. https://doi.org/10.1007/s00253-011-3372-6.
184. Solanki K, Grover N, Downs P, Paskaleva EE, Mehta KK, Lee L, Schadler LS, Kane RS, Dordick JS. 2013. Enzyme-based listericidal nanocomposites. Sci Rep 3:1584. https://doi.org/10.1038/srep01584.
185. Pavlukhina S, Lu Y, Patimetha A, Libera M, Sukhishvili S. 2010. Polymer multilayers with pH-triggered release of antibacterial agents. Biomacromolecules 11:3448-3456. https://doi.org/10.1021/bm100975w.
186. McCoy CP, Brady C, Cowley JF, McGlinchey SM, McGoldrick N, Kinnear DJ, Andrews GP, Jones DS. 2010. Triggered drug delivery from biomaterials. Expert Opin Drug Deliv 7:605-616. https://doi.org/10.1517/17425241003677731.
187. Pornpattananangkul D, Zhang L, Olson S, Aryal S, Obonyo M, Vecchio K, Huang C-M, Zhang L. 2011. Bacterial toxintriggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc 133:4132-4139. https://doi.org/10.1021/ja111110e.
188. Bean JE, Alves DR, Laabei M, Esteban PP, Thet NT, Enright MC, Jenkins ATA. 2014. Triggered release of bacteriophage K from agarose/hyaluronan hydrogel matrixes by Staphylococcus aureus virulence factors. Chem Mater 26:7201-7208. https://doi.org/10.1021/cm503974g.
189. Komnatnyy VV, Chiang WC, Tolker-Nielsen T, Givskov M, Nielsen TE. 2014. Bacteria-triggered release of antimicrobial agents. Angew Chem Int Ed Engl 53:439-441. https://doi.org/10.1002/anie.201307975.
190. Ashraf S, Park H-K, Park H, Lee S-H. 2016. Snapshot of phase transition in thermoresponsive hydrogel PNIPAM: role in drug delivery and tissue engineering. Macromol Res 24:297-304. https://doi.org/10.1007/s13233-016-4052-2.
191. Ji J, Hao S, Wu D, Huang R, Xu Y. 2011. Preparation, characterization Endolysins against Staphylococcal Infections and in vitro release of chitosan nanoparticles loaded with gentamicin and salicylic acid. Carbohydr Polym 85:803-808. https://doi.org/10.1016/j.carbpol.2011.03.051.
192. Huang Y-C, Li R-Y, Chen J-Y, Chen J-K. 2016. Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery. Carbohydr Polym 138:114-122. https://doi.org/10.1016/j.carbpol.2015.11.072.
193. Filatova LY, Donovan DM, Becker SC, Lebedev DN, Priyma AD, Koudriachova HV, Kabanov AV, Klyachko NL. 2013. Physicochemical characterization of the staphylolytic LysK enzyme in complexes with polyca-tionic polymers as a potent antimicrobial. Biochimie 95:1689-1696. https://doi.org/10.1016/j.biochi.2013.04.013.
194. Chaisri W, Ghassemi AH, Hennink WE, Okonogi S. 2011. Enhanced gentamicin loading and release of PLGA and PLHMGA microspheres by varying the formulation parameters. Colloids Surf B Biointerfaces 84: 508-514. https://doi.org/10.1016/j.colsurfb.2011.02.006.
195. Nash ME, Carroll WM, Velasco D, Gomez J, Gorelov AV, Elezov D, Gallardo A, Rochev YA, Elvira C. 2013. Synthesis and characterization of a novel thermoresponsive copolymer series and their application in cell and cell sheet regeneration. J Biomater Sci Polym Ed 24:253-268. https://doi.org/10.1080/09205063.2012.690274.
196. Zhou M, Liu S, Jiang Y, Ma H, Shi M, Wang Q, Zhong W, Liao W, Xing MM. 2015. Doxorubicinloaded single wall nanotube thermo-sensitive hydrogel for gastric cancer chemo-photothermal therapy. Adv Funct Mater 25:4730-4739. https://doi.org/10.1002/adfm.201501434.
197. Pawar MD, Rathna G, Agrawal S, Kuchekar BS. 2015. Bioactive thermo-responsive polyblend nanofiber formulations for wound healing. Mater Sci Eng C Mater Biol Appl 48:126-137. https://doi.org/10.1016/j.msec.2014.11.037.
198. Hathaway H, Alves DR, Bean J, Esteban PP, Ouadi K, Sutton JM, Jenkins ATA. 2015. Poly(N-isopropylacrylamidecoallylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of bacteriophage K. Eur J Pharm Biopharm 96:437-441. https://doi.org/10.1016/j.ejpb.2015.09.013.
199. Hathaway H, Ajuebor J, Stephens L, Coffey A, Potter U, Sutton JM, Jenkins ATA. 2017. Thermally triggered release of the bacteriophage endolysin CHAP K and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA). J Control Release 245:108-115. https://doi.org/10.1016/j.jconrel.2016.11.030.
200. Nelson D. 2012. Noninvasive thermal ablation of osteomyelitis-causing bacteria using functionalized nanoparticles, accession number ADA562458. University of Maryland, College Park, MD.
201. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacterio-phage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:2743-2750. https://doi.org/10.1128/AAC.02526-12.
202. Gilmer DB, Schmitz JE, Thandar M, Euler CW, Fischetti VA. 2017. The phage lysin PlySs2 decolonizes Streptococcus suis from murine intranasal mucosa. PLoS One 12:e0169180. https://doi.org/10.1371/journal.pone.0169180.
203. Lood R, Raz A, Molina H, Euler CW, Fischetti VA. 2014. A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob Agents Chemother 58:3073-3084. https://doi.org/10.1128/AAC.00115-14.
204. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sc i U S A 98: 4107-4112. https://doi.org/10.1073/pnas.061038398.
205. Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G. 2013. In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrob Agents Chemother 57:6276-6283. https://doi.org/10.1128/AAC.01701-13.
206. Doehn JM, Fischer K, Reppe K, Gutbier B, Tschernig T, Hocke AC, Fischetti VA, Löffler J, Suttorp N, Hippenstiel S. 2013. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J Antimicrob Chemother 68:2111-2117. https://doi.org/10.1093/jac/dkt131.
207. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294: 2170-2172. https://doi.org/10.1126/science.1066869.
208. Witzenrath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Müller H, Gutbier B, Schütte H. 2009. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 37:642-649. https://doi.org/10.1097/CCM.0b013e31819586a6.
209. Entenza J, Loeffler J, Grandgirard D, Fischetti V, Moreillon P. 2005. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49:4789-4792. https://doi.org/10.1128/AAC.49.11.4789-4792.2005.
210. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889. https://doi.org/10.1038/nature01026.
211. Yang H, Zhang Y, Yu J, Huang Y, Zhang X-E, Wei H. 2014. Novel chimeric lysin with highlevel antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 58:536-542. https://doi.org/10.1128/AAC.01793-13.
212. Díez-Martínez R, de Paz H, Bustamante N, García E, Menéndez M, García P. 2013. Improving the lethal effect of Cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob Agents Chemother 57: 5355-5365. https://doi.org/10.1128/AAC.01372-13.
213. Briers Y, Lavigne R. 2015. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol 10:377-390. https://doi.org/10.2217/fmb.15.8.
214. Chopra S, Harjai K, Chhibber S. 2016. Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. Int J Med Microbiol 306:707-716. https://doi.org/10.1016/j.ijmm.2016.08.003.
215. Zhang L, Li D, Li X, Hu L, Cheng M, Xia F, Gong P, Wang B, Ge J, Zhang H. 2016. LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Sci Rep 6:29344. https://doi.org/10.1038/srep29344.
216. Fan J, Zeng Z, Mai K, Yang Y, Feng J, Bai Y, Sun B, Xie Q, Tong Y, Ma J. 2016. Preliminary treatment of bovine mastitis caused by Staphylococcus aureus, with trx-SA1, recombinant endolysin of S. aureus bacteriophage IME-SA1. Vet Microbiol 191:65-71. https://doi.org/10.1016/j.vetmic.2016.06.001.
217. Totté JE, van Doorn MB, Pasmans SG. 2017. Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases. Case Rep Dermatol 9:19-25. https://doi.org/10.1159/000473872.
218. Shen Y, Barros M, Vennemann T, Gallagher DT, Yin Y, Linden SB, Heselpoth RD, Spencer DJ, Donovan DM, Moult J. 2016. A bacterio-phage endolysin that eliminates intracellular streptococci. eLife 5:e13152. https://doi.org/10.7554/eLife.13152.
219. Meng X, Shi Y, Ji W, Meng X, Zhang J, Wang H, Lu C, Sun J, Yan Y. 2011. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microbiol 77: 8272-8279. https://doi.org/10.1128/AEM.05151-11.
220. Hoopes JT, Stark CJ, Kim HA, Sussman DJ, Donovan DM, Nelson DC. 2009. Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi. Appl Environ Microbiol 75:1388-1394. https://doi.org/10.1128/AEM.02195-08.
221. Celia LK, Nelson D, Kerr DE. 2008. Characterization of a bacteriophage lysin (Ply700) from Streptococcus uberis. Vet Microbiol 130:107-117. https://doi.org/10.1016/j.vetmic.2007.12.004.
222. Hathaway H, Milo S, Sutton JM, Jenkins TA. 2017. Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins. Ther Deliv 8:543-556. https://doi.org/10.4155/tde-2017-0040.
223. Shavrina MS, Zimin AA, Molochkov NV, Chernyshov SV, Machulin AV, Mikoulinskaia GV. 2016. In vitro study of the antibacterial effect of the bacteriophage T5 thermostable endolysin on Escherichia coli cells. J Appl Microbiol 121:1282-1290. https://doi.org/10.1111/jam.13251.
224. Oliveira H, Boas DV, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J. 2016. Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad antigram-negative bacterial activity. Front Microbiol 7:208. https://doi.org/10.3389/fmicb.2016.00208.
225. Obeso JM, Martínez B, Rodríguez A, García P. 2008. Lytic activity of the recombinant staphylococcal bacteriophage H5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 128: 212-218. https://doi.org/10.1016/j.ijfoodmicro.2008.08.010.
226. Lai M-J, Lin N-T, Hu A, Soo P-C, Chen L-K, Chen L-H, Chang K-C. 2011. Antibacterial activity of Acinetobacter baumannii phage AB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria. Appl Microbiol Biotechnol 90:529-539. https://doi.org/10.1007/s00253-011-3104-y.
227. Son J-S, Lee S-J, Jun SY, Yoon SJ, Kang SH, Paik HR, Kang JO, Choi Y-J. 2010. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cellwall-degrading enzyme. Appl Microbiol Biotechnol 86:1439-1449. https://doi.org/10.1007/s00253-009-2386-9.
228. Seyed Hosseini E, Moniri R, Goli YD, Haddad Kashani H. 2016. Purification of antibacterial CHAPK protein using a selfcleaving fusion tag and its activity against methicillin-resistant Staphylococcus aureus. Probiotics Antimicrob Proteins 8:202–210. https://doi.org/10.1007/s12602-016-9236-8.
229. Haddad Kashani H, Moniri R. 2015. Expression of recombinant pET22b-LysK-cysteine/histidine-dependent amidohydrolase/peptidase bacteriophage therapeutic protein in Escherichia coli BL21 (DE3). Osong Public Health Res Perspect 6:256–260. https://doi.org/10.1016/j.phrp.2015.08.001.